Search

Displaying results 3761 - 3770 of 5900 in total
  1. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

  2. Drug

    Cedirogant

    go.drugbank.com/drugs/DB18951
    Investigational

    Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

  3. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  4. Drug

    Motexafin gadolinium

    go.drugbank.com/drugs/DB05428
    Investigational

    It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin. … It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells.

  5. Drug

    Atuliflapon

    go.drugbank.com/drugs/DB19029
    Investigational

    Atuliflapon is under investigation in clinical trial NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-severe Uncontrolled Asthma).

  6. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. … AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia

  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and

  9. Drug

    Granisetron

    go.drugbank.com/drugs/DB00889
    ApprovedInvestigational

    A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: GRANISETRON MYLAN GENERICS
  10. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.